Cost-Effectiveness of Pneumococcal Conjugate Vaccines 13 and Its High Impact in Public Health in Chinese Cities

January 2022

Pneumococcal disease (PD) is a serious public health problem in China with an estimated 30,000 deaths per year. Studies have reported the cost-effectiveness of pneumococcal conjugate vaccines (PCV) in China, yet they are not well characterized in specific cities at present.

An economic model was implemented to evaluate the cost-effectiveness of 70% of vaccination with PCV13 compared to no vaccination in seven Chinese cities. The base case analysis examined direct (reduction in vaccinated) and indirect (reduction in unvaccinated) effects (DE + IDE).

PCV13 was cost-effective in all 7 cities for both IDE + DE and DE-only scenarios. In addition, PCV13 remained cost-effective regardless of the dosing schedule. Also, PCV13 is projected to help prevent invasive PD, pneumonia, and otitis media as well as associated mortality for both the vaccinated and unvaccinated individuals through the DE and IDE.

The findings presented help formulate informed decisions by policymakers in the definition of the resource allocation in the respective cities. Though they are interesting both from an epidemiological and a public health perspective, vaccine funding in China is based on cities. As such, a stronger understanding of the national level and population-specific data are warranted for PCV13 to be incorporated into its broadly available national childhood immunization program.

Learn More

New Report: Recommendations for Patient and Family Engagement in Measure Development

Harnessing the stories, ideas, and innovations of patient and caregiver partners is the key to making measurement meaningful. With support from the Patient-Centered Outcomes Research Institute (PCORI)...
Learn More

About

About

Capabilities

Capabilities

Contact

Contact Us

Insights

Insights

Guy D’Andrea Speaks About Innovative Payment Models

Click here to view the VIDEO